# A Study of TRK-950 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct05423262/  
OnCo record `nct05423262` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TRK-950, Nivolumab in melanoma, run by Toray Industries, Inc, now recruiting.

## Summary

A Study of TRK-950 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05423262 by Toray Industries, Inc, with 49 participants planned, started 2022-07-06 and due to reach its primary completion in 2027-12. Interventions recorded: TRK-950, TRK-950, TRK-950, Nivolumab, TRK-950. Conditions listed: Solid Tumor, Melanoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05423262
- Phase: 1/2
- Setting: A Phase I/II Study of TRK-950 in Patients With Advanced Solid Tumors
- Sponsor: Toray Industries, Inc
- Enrolled: 49

## Sources

- ClinicalTrials.gov NCT05423262: https://clinicaltrials.gov/study/NCT05423262

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/), [TRK-950](https://onco.cc/drugs/trk-950/)

---
JSON: https://onco.cc/api/v1/entities/nct05423262.json